Options Brief: Celsion Corporation

Shares of Celsion Corporation CLSN are lower on the session by 5.90%, trading at $3.03. Overall call volume is now running at 4.55x the daily average, with 5% of all calls traded being purchases on the offer. 3,816 contracts have traded on the session so far. Celsion Corporation s an oncology drug development company focused on improving treatment for those suffering with aggressive and difficult to treat forms of cancer. Its lead product ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer and a Phase II study for recurrent chest wall breast cancer.